Lactoferrin Adsorbed onto Biomimetic Hydroxyapatite Nanocrystals Controlling - In Vivo - the Helicobacter pylori Infection

BackgroundThe resistance of Helicobacter pylori to the antibiotic therapy poses the problem to discover new therapeutic approaches. Recently it has been stated that antibacterial, immunomodulatory, and antioxidant properties of lactoferrin are increased when this protein is surface-linked to biomimetic hydroxyapatite nanocrystals.ObjectiveBased on these knowledge, the aim of the study was to investigate the efficacy of lactoferrin delivered by biomimetic hydroxyapatite nanoparticles with cell free supernatant from probiotic Lactobacillus paracasei as an alternative therapy against Helicobacter pylori infection.MethodsAntibacterial and antinflammatory properties, humoral antibody induction, histopathological analysis and absence of side effects were evaluated in both in vitro and in vivo studies.ResultsThe tests carried out have been demonstrated better performance of lactoferrin delivered by biomimetic hydroxyapatite nanoparticles combined with cell free supernatant from probiotic Lactobacillus paracasei compared to both lactoferrin and probiotic alone or pooled.ConclusionThese findings indicate the effectiveness and safety of our proposed therapy as alternative treatment for Helicobacter pylori infection.背景：幽门螺杆菌（Helicobacter pylori）对抗生素治疗的耐药性问题亟待开发新型治疗策略。近日已有研究证实，当乳铁蛋白（lactoferrin）与仿生羟基磷灰石纳米晶（biomimetic hydroxyapatite nanocrystals）结合于表面时，其抗菌、免疫调节及抗氧化活性显著增强。 研究目的：基于上述研究成果，本研究旨在探究由仿生羟基磷灰石纳米颗粒递送的乳铁蛋白，联合副干酪乳杆菌（Lactobacillus paracasei）益生菌无细胞上清液（cell free supernatant），作为抗幽门螺杆菌感染替代疗法的疗效。 研究方法：本研究通过体外（in vitro）与体内（in vivo）实验，分别评估其抗菌、抗炎活性，体液抗体诱导反应，组织病理学分析及不良反应发生情况。 研究结果：实验结果表明，相较于单独使用乳铁蛋白、单独使用益生菌或二者联合使用的方案，联合仿生羟基磷灰石纳米颗粒递送的乳铁蛋白与副干酪乳杆菌益生菌无细胞上清液的复合疗法疗效更为优异。 结论：本研究结果证实，该新型疗法可有效且安全地用于幽门螺杆菌感染的替代治疗。